Welcome to LookChem.com Sign In|Join Free
  • or
3,6-Dimethoxy-2-Nitrobenzaldehyde is a chemical compound that serves as an intermediate in the synthesis of various pharmaceuticals and complex organic compounds. It is characterized by a benzene ring with two methoxy groups, a nitro group, and a formyl group, which contribute to its reactivity in organic synthesis.

1206-55-9

Post Buying Request

1206-55-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1206-55-9 Usage

Uses

Used in Organic Synthesis:
3,6-Dimethoxy-2-Nitrobenzaldehyde is used as an intermediate for the synthesis of various organic compounds. Its chemical structure allows it to participate in reactions such as Friedel-Crafts acylation and the Vilsmeier-Haack reaction, making it a valuable building block in the production of complex molecules.
Used in Pharmaceutical Industry:
3,6-Dimethoxy-2-Nitrobenzaldehyde is used as a key component in the synthesis of various pharmaceuticals. Its versatility in organic synthesis enables the creation of a wide range of drug molecules, contributing to the development of new treatments and therapies.
Used in Porphyrin-based Photosensitizer Production:
3,6-Dimethoxy-2-Nitrobenzaldehyde is used as a building block in the production of porphyrin-based photosensitizers. These photosensitizers are important in the field of photodynamic therapy, a medical treatment that uses light to activate a drug to kill cancer cells or other harmful organisms. 3,6-DIMETHOXY-2-NITROBENZALDEHYDE's reactivity and structural features make it suitable for the synthesis of these therapeutic agents.

Check Digit Verification of cas no

The CAS Registry Mumber 1206-55-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,0 and 6 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1206-55:
(6*1)+(5*2)+(4*0)+(3*6)+(2*5)+(1*5)=49
49 % 10 = 9
So 1206-55-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO5/c1-14-7-3-4-8(15-2)9(10(12)13)6(7)5-11/h3-5H,1-2H3

1206-55-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3,6-dimethoxy-2-nitrobenzaldehyde

1.2 Other means of identification

Product number -
Other names 3,6-dimethoxy-2-nitro-benzaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1206-55-9 SDS

1206-55-9Downstream Products

1206-55-9Relevant academic research and scientific papers

Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma

Kuang, Yuting,Sechi, Mario,Nurra, Salvatore,Ljungman, Mats,Neamati, Nouri

, p. 1576 - 1594 (2018)

Altering redox homeostasis provides distinctive therapeutic opportunities for the treatment of pancreatic cancer. Quinazolinediones (QDs) are novel redox modulators that we previously showed to induce potent growth inhibition in pancreatic ductal adenocarcinoma (PDAC) cell lines. Our lead optimization campaign yielded QD325 as the most potent redox modulator candidate inducing substantial reactive oxygen species (ROS) in PDAC cells. Nascent RNA sequencing following treatments with the QD compounds revealed induction of stress responses in nucleus, endoplasmic reticulum, and mitochondria of pancreatic cancer cells. Furthermore, the QD compounds induced Nrf2-mediated oxidative stress and unfolded protein responses as demonstrated by dose-dependent increases in RNA synthesis of representative genes such as NQO1, HMOX1, DDIT3, and HSPA5. At higher concentrations, the QDs blocked mitochondrial function by inhibiting mtDNA transcription and downregulating the mtDNA-encoded OXPHOS enzymes. Importantly, treatments with QD325 were well tolerated in vivo and significantly delayed tumor growth in mice. Our study supports the development of QD325 as a new therapeutic in the treatment of PDAC.

A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species

Hu, Shuai,Sechi, Mario,Singh, Pankaj Kumar,Dai, Lipeng,Mccann, Sean,Sun, Duxin,Ljungman, Mats,Neamati, Nouri

, p. 9838 - 9855 (2020)

Redox modulators have been developed as an attractive approach to treat cancer. Herein, we report the synthesis, identification, and biological evaluation of a quinazolinedione reactive oxygen species (ROS) inducer, QD394, with significant cytotoxicity in pancreatic cancer cells. QD394 shows a transcriptomic profile remarkably similar to napabucasin, a cancer stemness inhibitor. Both small molecules inhibit STAT3 phosphorylation, increase cellular ROS, and decrease the GSH/GSSG ratio. Moreover, QD394 causes an iron- and ROS-dependent, GPX4 mediated cell death, suggesting ferroptosis as a major mechanism. Importantly, QD394 decreases the expression of LRPPRC and PNPT1, two proteins involved in mitochondrial RNA catabolic processes and both negatively correlated with the overall survival of pancreatic cancer patients. Pharmacokinetics-guided lead optimization resulted in the derivative QD394-Me, which showed improved plasma stability and reduced toxicity in mice compared to QD394. Overall, QD394 and QD394-Me represent novel ROS-inducing drug-like compounds warranting further development for the treatment of pancreatic cancer.

Synthesis and cytotoxicity of analogues of the antibiotic BE 10988 inhibitors of DNA topoisomerase II

Catrycke, Marc-Olivier,Houssin, Raymond,Henichart, Jean-Pierre,Pfeiffer, Bruno,Renard, Pierre,Dassonneville, Laurent,Bailly, Christian

, p. 2025 - 2030 (1999)

Indolequinone derivatives of the antitumour antibiotic BE 10988 were synthesized and evaluated for their cytotoxicity and action mechanism. The quinone system is essential to biological activity and the thiazole ring plays a major role in the poisoning of

Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Kong, Kai-min,Liu, Bing-zhi,Meng, Guang-rong,Zhang, Jia-wei,Zhang, Qian

, (2019)

Early studies demonstrated that over expression of indoleamine 2,3-dioxygenase (IDO1) in tumor microenvironment results in tumor immune escape. Herein, in order to simplify the structure of two kinds of IDO1 inhibitors from marine alkaloid, Exiguamine A and Tsitsikammamines, we designed, synthesized a series of 1H-indole-4,7-dione derivatives and evaluated their inhibitory activity in IDO1 enzyme and in IFN-γ stimulated Hela cells in vitro. The structure-activity relationship demonstrated that 5-(pyridin-3-yl)-1H-indole-4,7-dione is a promising scaffold for IDO1 inhibitors and most compounds with this core showed moderate inhibition potency at micromole level. Our further enzyme kinetics experiments reveal that these new developed compounds might act as reversible competitive inhibitors of IDO1.

Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells

Sanna, Vanna,Nurra, Salvatore,Pala, Nicolino,Marceddu, Salvatore,Pathania, Divya,Neamati, Nouri,Sechi, Mario

, p. 5209 - 5220 (2016)

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease. Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage. We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells. Previously, we discovered a novel class of compounds (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling. Herein, we prepared novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1. Similarly, we prepared QD-based NPs densely decorated with an isatoic anhydride derivative. Furthermore, we evaluated their impact on ligand binding and antiproliferative activity against PDAC cells. The targeted NPs were more potent than the nontargeted constructs in PDAC cells warranting further development.

Re-examination of the synthesis of 3,5-dimethoxy-2-nitrobenzaldehyde

Del Mar Blanco,Avendano,Cabezas,Menendez

, p. 1351 - 1356 (1993)

An efficient and reproducible synthetic method is proposed for the preparation of 2-nitro-3,6-dimethoxybenzaldehyde.

SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY

-

Page/Page column 58; 61, (2017/09/27)

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazolinedione structure which function as reactive oxygen species (ROS) inducers and inhibitors of mitochondrial activity within cancer cells (e.g., pancreatic cancer cells), and their use as therapeutics for the treatment of cancer (e.g., pancreatic cancer) and other diseases.

Triazolo Quinazoline Dione Derivatives

-

Paragraph 0082-0087, (2018/04/06)

The present invention relates to a triazolo quinazolinedione derivative. A novel synthesized triazolo quinazolinedione derivative inhibits proliferation of cancer cells, and an anticancer activity is shown in a living organism. Accordingly, a compound of the present invention can be useful in the cancer treatment field. The compound has a chemical structure of chemical formula 1.COPYRIGHT KIPO 2017

Novel indole derivative and medicine containing the same (by machine translation)

-

Paragraph 0152; 0155, (2018/06/30)

[A] formation of Amyloid fibrils can be compounds, including therapeutic or prophylactic agent for neurodegenerative disease Amyloid fibrils formation inhibitor compound and of. (I) or its pharmaceutically acceptable compound represented by the formula [a] or a salt or solvate thereof includes the, Amyloid fibrils formation inhibitor. [R1 And R2 Each independently is H, an alkyl group, a cyano group or the like; R3 And R4 Each independently is H, or an alkyl group; R3 And R4 The, joint may form a ring; Ar1 And Ar2 The substituted or unsubstituted heteroaryl group are independently substituted/unsubstituted aryl groups /; X and Y are each independently a single bond, - (=O) - C etc., Z is O or CH2 ; N is an integer of 1 - 3][Drawing] no (by machine translation)

Synthesis and antiproliferative activity of new cytotoxic tri- and tetraazabenzo[3,2-a]fluorene-5,6-dione derivatives

Leepasert, Theerachart,Shahabi, Manochehr,Shanab, Karem,Schirmer, Eva,Holzer, Wolfgang,Spreitzer, Helmut,Aicher, Babette,Mueller, Gilbert,Guenther, Eckhard

, p. 5264 - 5266 (2013/09/23)

A new series of substituted tri-/tetraazabenzo[3,2-a]fluorene-5,6-diones and their corresponding oxime derivatives have been synthesized and spectroscopically characterized. The antiproliferative activities of all compounds were evaluated on at least thre

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1206-55-9